Indicators of prescribing quality in drug utilisation research: report of a European meeting (DURQUIM, 13-15 May 2004)

被引:37
作者
Hoven, JL
Haaijer-Ruskamp, FM
Vander Stichele, RH
机构
[1] Univ Ghent, Heymans Inst Pharmacol, B-9000 Ghent, Belgium
[2] Univ Groningen, Dept Clin Pharmacol, NL-9700 AB Groningen, Netherlands
关键词
drug utilization; drug prescribing; health care; validity assessment; quality indicators; Europe;
D O I
10.1007/s00228-004-0845-x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
An invitational expert meeting on indicators of prescribing quality was held on 13-15 May 2004, bringing together-from 19 European countries, the US, Canada, and Australia-40 researchers specialized in the development and application of indicators. The meeting was organized by the European Drug Utilization Research Group (EuroDURG), the Belgian National Health Insurance Institute (RIZIV-INAMI), and the World Health Organisation Regional Office for Europe (WHO-Euro). The field of prescribing quality was defined and delineated from the medical error field. A conceptual grid for classifying quality indicators was discussed, combining two axes (a drug/disease/patient axis and a structure/process/outcome axis). In addition, available databases were listed for continuous monitoring of drug utilization in Europe, with a description of the content and the richness of the collected data, as well as the impact on the potential and limitations to develop quality indicators. The importance of the origin of data for validity assessment was stressed, as data on drug utilization may originate from physician sources (prescribing data), from pharmacist or health insurer sources (distribution data), or directly from patient sources (compliance data). The different aspects of validity and their methods of assessment were listed. An overview of the (in)appropriate uses of indicators was given. The state of the art of the development and application of prescribing quality indicators in all represented countries was made, together with a first draft of a database of prescribing quality indicators, already subjected to validation procedures.
引用
收藏
页码:831 / 834
页数:4
相关论文
共 7 条
[1]   WHAT CONSTITUTES GOOD PRESCRIBING [J].
BARBER, N .
BRITISH MEDICAL JOURNAL, 1995, 310 (6984) :923-925
[2]   Deviations from evidence-based prescribing of non-steroidal anti-inflammatory drugs in three European regions [J].
Bergman, U ;
Andersen, M ;
Vaccheri, A ;
Bjerrum, L ;
Wettermark, B ;
Montanaro, N .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 56 (03) :269-272
[3]  
HAAIJERRUSKAMP F, 2004, CONCEPTUAL FRAMEWORK
[4]  
Lawrence M., 1997, Eur J Gen Pract, V3, P103, DOI [DOI 10.3109/13814789709160336, 10.3109/13814789709160336]
[5]  
MCGAEVOCK H, 2000, HDB DRUG USE RES MET
[6]   European Surveillance of Antimicrobial Consumption (ESAC): Data collection performance and methodological approach [J].
Vander Stichele, RH ;
Elseviers, MM ;
Ferech, M ;
Blot, S ;
Goossens, H .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 58 (04) :419-428
[7]   Variations and increase in use of statins across Europe: data from administrative databases [J].
Walley, T ;
Folino-Gallo, P ;
Schwabe, U ;
van Ganse, E .
BRITISH MEDICAL JOURNAL, 2004, 328 (7436) :385-386